HRP20201479T1 - Postupci pripreme citotoksičnih derivata benzodiazepina - Google Patents

Postupci pripreme citotoksičnih derivata benzodiazepina Download PDF

Info

Publication number
HRP20201479T1
HRP20201479T1 HRP20201479TT HRP20201479T HRP20201479T1 HR P20201479 T1 HRP20201479 T1 HR P20201479T1 HR P20201479T T HRP20201479T T HR P20201479TT HR P20201479 T HRP20201479 T HR P20201479T HR P20201479 T1 HRP20201479 T1 HR P20201479T1
Authority
HR
Croatia
Prior art keywords
formula
compound
image
monomer
reacting
Prior art date
Application number
HRP20201479TT
Other languages
English (en)
Croatian (hr)
Inventor
Baudouin GÉRARD
Manami Shizuka
Michael Louis Miller
Richard A. Silva
Original Assignee
Immunogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen, Inc. filed Critical Immunogen, Inc.
Publication of HRP20201479T1 publication Critical patent/HRP20201479T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
    • C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
HRP20201479TT 2015-07-21 2016-07-21 Postupci pripreme citotoksičnih derivata benzodiazepina HRP20201479T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562195023P 2015-07-21 2015-07-21
US201662327973P 2016-04-26 2016-04-26
PCT/US2016/043414 WO2017015502A1 (en) 2015-07-21 2016-07-21 Methods of preparing cytotoxic benzodiazepine derivatives
EP16745598.9A EP3325482B1 (en) 2015-07-21 2016-07-21 Methods of preparing cytotoxic benzodiazepine derivatives

Publications (1)

Publication Number Publication Date
HRP20201479T1 true HRP20201479T1 (hr) 2020-12-11

Family

ID=56557925

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201479TT HRP20201479T1 (hr) 2015-07-21 2016-07-21 Postupci pripreme citotoksičnih derivata benzodiazepina

Country Status (23)

Country Link
US (11) US9873708B2 (enExample)
EP (7) EP3778602B1 (enExample)
JP (8) JP6858745B2 (enExample)
KR (5) KR102660070B1 (enExample)
CN (5) CN108055844A (enExample)
AU (7) AU2016297607A1 (enExample)
CA (4) CA2991326A1 (enExample)
CY (2) CY1122553T1 (enExample)
DK (2) DK3325483T3 (enExample)
ES (4) ES2820358T3 (enExample)
HK (1) HK1252322A1 (enExample)
HR (1) HRP20201479T1 (enExample)
HU (1) HUE051541T2 (enExample)
IL (10) IL305989A (enExample)
LT (2) LT3325483T (enExample)
PL (2) PL3325483T3 (enExample)
PT (2) PT3325482T (enExample)
RS (2) RS60840B1 (enExample)
RU (3) RU2018105752A (enExample)
SG (2) SG10202009354SA (enExample)
SI (2) SI3325483T1 (enExample)
SM (2) SMT202000004T1 (enExample)
WO (3) WO2017015502A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102660070B1 (ko) 2015-07-21 2024-04-24 이뮤노젠 아이엔씨 세포독성 벤조다이아제핀 유도체의 제조 방법
CN118099069A (zh) 2016-03-22 2024-05-28 Ev 集团 E·索尔纳有限责任公司 用于衬底的接合的装置和方法
KR102617264B1 (ko) 2016-10-19 2023-12-29 인벤라 인코포레이티드 항체 구조물
JP7681879B2 (ja) 2016-12-22 2025-05-23 ウニヴェルシタ・デリ・ストゥディ・マニャ・グレチア・カタンツァーロ Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体
KR102480594B1 (ko) * 2017-01-25 2022-12-26 이뮤노젠 아이엔씨 세포독성 벤조디아제핀 유도체를 제조하는 방법
CA3102349A1 (en) 2018-06-05 2019-12-12 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
KR20210099010A (ko) * 2018-11-12 2021-08-11 이뮤노젠 아이엔씨 세포독성 벤조디아제핀 유도체의 제조 방법
AU2019379104A1 (en) 2018-11-12 2021-06-03 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
CN113661172A (zh) * 2019-03-29 2021-11-16 伊缪诺金公司 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物
US20250367307A1 (en) 2022-06-30 2025-12-04 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763183A (en) 1972-07-10 1973-10-02 Sterling Drug Inc 1,2,3,10,11,11a-hexahydro-5h-pyrrolo (2,1-c)(1,4)benzodiazepines
US3860600A (en) 1972-07-10 1975-01-14 Sterling Drug Inc Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines
US4678784A (en) 1984-04-11 1987-07-07 Mcneilab, Inc. Method for the treatment of LHRH diseases and conditions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9205051D0 (en) 1992-03-09 1992-04-22 Cancer Res Campaign Tech Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
CA2341471C (en) 1998-08-27 2009-04-07 Spirogen Limited Pyrrolbenzodiazepines
NZ517772A (en) 1999-11-24 2004-03-26 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
US6548042B2 (en) * 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
UA75093C2 (en) * 2000-10-06 2006-03-15 Dimensional Pharm Inc Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
JP2005539009A (ja) 2002-08-02 2005-12-22 イミュノジェン・インコーポレーテッド 新規の効力のあるタキサンを含む細胞毒性物質、および、それらの治療用途
DE60336149D1 (de) 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
RU2338747C2 (ru) 2003-03-31 2008-11-20 Каунсил Оф Сайентифик Энд Индастриал Рисерч ДИМЕРЫ ПИРРОЛО [2, 1-c][1, 4] БЕНЗОДИАЗЕПИНА В КАЧЕСТВЕ ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
RU2314309C2 (ru) 2003-03-31 2008-01-10 Каунсил Оф Сайентифик Энд Индастриал Рисерч Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе
WO2004087716A1 (en) 2003-03-31 2004-10-14 Council Of Scientific And Industrial Research Pyrrolo[(2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof
ATE421967T1 (de) 2003-03-31 2009-02-15 Council Scient Ind Res Nichtvernetzende pyrroloä2,1-cüä1, 4übenzodiazepine als potentielle antitumor- agentien und ihre herstellung
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
WO2005040170A2 (en) 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
WO2005063759A1 (en) 2003-12-31 2005-07-14 Council Of Scientific And Industrial Research PROCESS FOR PREPARING PYRROLO[2, 1-c] [1, 4] BENZODIAZEPINE HYBRIDS
CA2558195C (en) * 2004-03-01 2012-11-06 Spirogen Limited 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines
GB0404578D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0410725D0 (en) 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
GB0412492D0 (en) * 2004-06-04 2004-07-07 Sterix Ltd Compound
NZ563136A (en) 2005-04-21 2009-11-27 Spirogen Ltd Pyrrolobenzodiazepines
GB0508084D0 (en) * 2005-04-21 2005-06-01 Spirogen Ltd Pyrrolobenzodiazepines
US8637664B2 (en) 2005-10-05 2014-01-28 Spirogen Sarl Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
RU2467007C2 (ru) * 2005-12-21 2012-11-20 Эбботт Лэборетриз Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
JP2009526778A (ja) 2006-02-13 2009-07-23 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ 抗腫瘍剤としてのビス−ピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−アントラキノン抱合体およびその製造方法
CL2007001536A1 (es) 2006-05-30 2008-01-25 Genentech Inc Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b.
SI2019104T1 (sl) 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
ATE543826T1 (de) 2007-08-01 2012-02-15 Council Scient Ind Res Als selektive antitumormittel geeignete pyrroloä2,1-cüä1,4übenzodiazepinglycosid-prodru s
HUE034763T2 (en) 2008-04-30 2018-02-28 Immunogen Inc Crosslinkers and their use
CN102083461B (zh) 2008-04-30 2014-09-17 伊缪诺金公司 有效的偶联物和亲水性连接体
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
GB0822260D0 (en) * 2008-12-05 2009-01-14 Merten Christoph Assay
US8637558B2 (en) * 2008-12-30 2014-01-28 Industry-Academic Cooperation Foundation, Chosun University Thiazolidinedione derivative and use thereof
SG173152A1 (en) 2009-02-05 2011-08-29 Immunogen Inc Novel benzodiazepine derivatives
KR20120080611A (ko) 2009-10-06 2012-07-17 이뮤노젠 아이엔씨 효능 있는 접합체 및 친수성 링커
US8314250B2 (en) * 2009-11-24 2012-11-20 Hoffmann-La Roche Inc. Sultam derivatives
JP5721180B2 (ja) * 2009-12-08 2015-05-20 国立大学法人岐阜大学 芳香族化合物、並びに、それを用いたオリゴヌクレオチド誘導体合成用修飾担体、オリゴヌクレオチド誘導体及びオリゴヌクレオチド構築物
US8962279B2 (en) * 2009-12-30 2015-02-24 Intel Corporation Solid-phase chelators and electronic biosensors
PL2536706T3 (pl) * 2010-02-11 2017-10-31 Celgene Corp Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
TWI672318B (zh) 2010-02-24 2019-09-21 美商免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
ES2623057T3 (es) 2010-04-15 2017-07-10 Medimmune Limited Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas
KR101772354B1 (ko) * 2010-04-15 2017-08-28 시애틀 지네틱스, 인크. 표적화된 피롤로벤조디아제핀 접합체
KR20190089048A (ko) 2011-02-15 2019-07-29 이뮤노젠 아이엔씨 컨쥬게이트의 제조방법
CN102234253B (zh) * 2011-06-02 2013-07-03 重庆莱美药业股份有限公司 一种制备非布索坦中间体的方法
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
EP3052464B1 (en) 2013-10-04 2020-04-15 Novartis AG 3'end caps for rna-interferring agents for use in rna interference
CN104628772A (zh) * 2013-11-07 2015-05-20 四川恒康发展有限责任公司 一种抗肿瘤前药及其激活剂、组合物和应用
CN103664896B (zh) * 2013-11-25 2016-03-02 济南精合医药科技有限公司 一种抗肿瘤分子靶向药物克里唑替尼的合成工艺方法
US9381256B2 (en) 2014-09-03 2016-07-05 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
US10988531B2 (en) 2014-09-03 2021-04-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9669102B2 (en) 2014-09-03 2017-06-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
KR102660070B1 (ko) * 2015-07-21 2024-04-24 이뮤노젠 아이엔씨 세포독성 벤조다이아제핀 유도체의 제조 방법
EP3380525B1 (en) * 2015-11-25 2023-11-08 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof

Also Published As

Publication number Publication date
RU2727151C2 (ru) 2020-07-21
US10392407B2 (en) 2019-08-27
KR20180038460A (ko) 2018-04-16
IL256860A (en) 2018-03-29
IL305279A (en) 2023-10-01
CA2991305C (en) 2024-03-12
EP3653628B1 (en) 2022-09-14
KR102659706B1 (ko) 2024-04-23
KR20240055894A (ko) 2024-04-29
SMT202000506T1 (it) 2020-11-10
JP7337114B2 (ja) 2023-09-01
IL283355B (en) 2022-08-01
HK1252322A1 (zh) 2019-05-24
IL276630B (en) 2021-06-30
EP4286387A2 (en) 2023-12-06
WO2017015502A8 (en) 2017-03-02
HK1252323A1 (en) 2019-05-24
JP6995178B2 (ja) 2022-02-21
CN108026103A (zh) 2018-05-11
PL3325482T3 (pl) 2021-01-11
CN108290895A (zh) 2018-07-17
IL286788A (en) 2021-10-31
AU2023201339A1 (en) 2023-04-06
AU2021202403B2 (en) 2022-12-08
US10787463B2 (en) 2020-09-29
IL276631A (en) 2020-09-30
EP3325482A1 (en) 2018-05-30
KR102660070B1 (ko) 2024-04-24
AU2016297607A1 (en) 2018-02-08
WO2017015502A1 (en) 2017-01-26
AU2016297608B2 (en) 2021-02-18
US10370389B2 (en) 2019-08-06
LT3325483T (lt) 2020-01-27
EP4163284A1 (en) 2023-04-12
AU2023202221A1 (en) 2023-05-04
US10081640B2 (en) 2018-09-25
RS59806B1 (sr) 2020-02-28
EP3325482B1 (en) 2020-06-24
DK3325483T3 (da) 2020-01-20
US20180201626A1 (en) 2018-07-19
KR20240055903A (ko) 2024-04-29
IL256854A (en) 2018-03-29
WO2017015496A1 (en) 2017-01-26
RU2018105756A (ru) 2019-08-21
US20170050985A1 (en) 2017-02-23
US20170051011A1 (en) 2017-02-23
IL305989A (en) 2023-11-01
IL294651B1 (en) 2023-10-01
IL256860B (en) 2020-08-31
JP6858745B2 (ja) 2021-04-14
JP2022046542A (ja) 2022-03-23
JP2021100959A (ja) 2021-07-08
AU2016297608A1 (en) 2018-02-08
EP3325483B1 (en) 2019-10-02
US11420982B2 (en) 2022-08-23
KR20180026741A (ko) 2018-03-13
US20190010169A1 (en) 2019-01-10
JP2018526340A (ja) 2018-09-13
US9890179B2 (en) 2018-02-13
CA2992082A1 (en) 2017-01-26
RU2018105756A3 (enExample) 2019-12-23
CA3227588A1 (en) 2017-01-26
CA2991305A1 (en) 2017-01-26
EP3778602A1 (en) 2021-02-17
AU2021203148A1 (en) 2021-06-10
RU2018105609A3 (enExample) 2020-04-30
EP3778602B1 (en) 2023-07-12
IL286788B2 (en) 2024-01-01
US9873708B2 (en) 2018-01-23
RU2018105752A (ru) 2019-08-21
JP2023166434A (ja) 2023-11-21
IL294651B2 (en) 2024-02-01
CN108290895B (zh) 2021-03-19
JP7334228B2 (ja) 2023-08-28
WO2017015495A1 (en) 2017-01-26
HUE051541T2 (hu) 2021-03-01
CY1122553T1 (el) 2021-01-27
US20190389883A1 (en) 2019-12-26
US20190112320A1 (en) 2019-04-18
CN113004288A (zh) 2021-06-22
US20210171546A1 (en) 2021-06-10
US20170050986A1 (en) 2017-02-23
SI3325483T1 (sl) 2020-03-31
IL276630A (en) 2020-09-30
EP3325485A1 (en) 2018-05-30
IL256861A (en) 2018-03-29
IL256861B (en) 2020-08-31
LT3325482T (lt) 2020-11-25
RS60840B1 (sr) 2020-10-30
PL3325483T3 (pl) 2020-05-18
US20200017526A1 (en) 2020-01-16
RU2018105752A3 (enExample) 2019-12-30
JP2018522018A (ja) 2018-08-09
IL276631B (en) 2021-10-31
IL283355A (en) 2021-07-29
AU2016297087A1 (en) 2018-02-08
CY1123390T1 (el) 2022-03-24
ES2820358T3 (es) 2021-04-20
AU2021202403A1 (en) 2021-05-20
SI3325482T1 (sl) 2020-11-30
JP2021035958A (ja) 2021-03-04
CN113087763A (zh) 2021-07-09
EP3325483A1 (en) 2018-05-30
RU2018105609A (ru) 2019-08-26
ES2959741T3 (es) 2024-02-28
CA2991326A1 (en) 2017-01-26
KR20180038461A (ko) 2018-04-16
SMT202000004T1 (it) 2020-03-13
EP4286387A3 (en) 2024-02-21
IL294651A (en) 2022-09-01
SG10202009354SA (en) 2020-11-27
IL286788B1 (en) 2023-09-01
SG10202106529XA (en) 2021-07-29
DK3325482T3 (da) 2020-09-28
ES2933376T3 (es) 2023-02-06
JP2018524387A (ja) 2018-08-30
JP2023162264A (ja) 2023-11-08
RU2746322C2 (ru) 2021-04-12
US10899775B2 (en) 2021-01-26
HK1252321A1 (en) 2019-05-24
US20230257400A1 (en) 2023-08-17
CN108026103B (zh) 2021-04-16
EP3653628A1 (en) 2020-05-20
EP3325485B1 (en) 2020-04-08
ES2764548T3 (es) 2020-06-03
AU2021203148B2 (en) 2023-01-12
PT3325482T (pt) 2020-09-24
JP6787995B2 (ja) 2020-11-18
PT3325483T (pt) 2020-01-15
CN108055844A (zh) 2018-05-18
AU2016297087B2 (en) 2021-02-18
US20210171547A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
HRP20201479T1 (hr) Postupci pripreme citotoksičnih derivata benzodiazepina
HRP20171899T1 (hr) N-acilsulfonamidni promotori apoptoze
HRP20191249T1 (hr) Procesi za pripremu (s)-1-(3-etoksi-4metoksifenil)-2-metansulfoniletilamina
HRP20200561T1 (hr) Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti
HRP20130300T1 (hr) Postupak za pripravu 4-[2-(2-fluorofenoksimetil)fenil]piperidin spojeva
JP2018522018A5 (enExample)
MEP10509A (en) Process for preparing n-alkyl naltrexone halides
ME02458B (me) Postupci i intermedijeri za spravljanje jak inhibitora
JP2010519351A5 (enExample)
GB1139918A (en) Dialkylamine derivatives, polymers produced therefrom and their use as flocculating agents
BR112013004827A2 (pt) "processo para a produção de derivados de 1-triazol-2-butanol"
BR112012024792A2 (pt) processo de preparo de derivados de sulfonamido-benzofurano
HRP20200037T1 (hr) TABLETA KOJA SADRŽI 7-[4- (4-BENZO [b] TIOFEN-4-YL-PIPERAZIN-1-YL) BUTOKSI]-1H-KINOLIN-2-ON ILI NJEGOVU SOL
JP2018520994A5 (enExample)
BR112014009190A2 (pt) formulação, uso de uma formulação, e, processo para a preparação de uma formulação
HRP20160518T1 (hr) Postupci za proizvodnju farmaceutske djelatne tvari
CN103611466B (zh) 一种无盐表面活性剂粘弹溶液的制备方法
JP2008540414A5 (enExample)
RU2015139961A (ru) Оптические отбеливающие агенты для высококачественной струйной печати
HRP20192289T1 (hr) Postupci za pripravu citotoksičnih derivata benzodiazepina
HRP20170023T1 (hr) Kristalni oblik pemirolasta
HRP20201952T1 (hr) Mješovite soli hidroksi-alkanske sulfinske kiseline
ME02590B (me) N- [4-(hinolin-4-iloksi)cikloheksil(metil)] (hetero)arilkarboksamidi kao antagonisti androgenog receptora, njihova proizvodnja i upotreba kao medicinski produkti
CN102746235A (zh) 一种改进的制备咪达那新的方法
AR079299A1 (es) Mejora de los procesos para la preparacion de granulos solubles de las sales de los acidos carboxilicos que contienen piridina